Car-t therapy is a kind of immunotherapy in which a chimeric antigen receptor that can specifically recognize tumor-associated antigens and simultaneously activate T cells is implanted into T lymphocytes of patients through genetic engineering technology such as viral vector or electroporation, and the CAR T cells are purified in vitro, amplified and then transfused again to inhibit and kill tumors. ShenZhen Cell Valley provides R&D and outsourcing production services for CAR-T cells with different targets, and the retroviral vector of cell valley is used for preparation. At present, many CAR-T cells targeting CD19, CD38, BCMA-CD38 and other double targets have been successfully prepared using the independently produced retroviral vectorand its transduction efficiency can reach more than 70%. It can complete the whole process service from T lymphocyte collection, tumor target virus vector transduction, CAR-T cell expansion, safety detection to release. At present, it has provided GMP-level CAR T cell production services to Huazhong University of Science and Technology Shenzhen Hospital.